EP1668002A4 - 2,4-dioxo-3-quinazolinylaryl sulfonylureas - Google Patents
2,4-dioxo-3-quinazolinylaryl sulfonylureasInfo
- Publication number
- EP1668002A4 EP1668002A4 EP04789522A EP04789522A EP1668002A4 EP 1668002 A4 EP1668002 A4 EP 1668002A4 EP 04789522 A EP04789522 A EP 04789522A EP 04789522 A EP04789522 A EP 04789522A EP 1668002 A4 EP1668002 A4 EP 1668002A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sub
- sup
- group
- alkyl
- member selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Non-Alcoholic Beverages (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL04789522T PL1668002T3 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50856403P | 2003-10-03 | 2003-10-03 | |
PCT/US2004/032921 WO2005032488A2 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1668002A2 EP1668002A2 (en) | 2006-06-14 |
EP1668002A4 true EP1668002A4 (en) | 2006-12-20 |
EP1668002B1 EP1668002B1 (en) | 2009-11-11 |
Family
ID=34421757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04789522A Active EP1668002B1 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Country Status (16)
Country | Link |
---|---|
US (1) | US7109332B2 (en) |
EP (1) | EP1668002B1 (en) |
JP (1) | JP2007507551A (en) |
KR (1) | KR20060113700A (en) |
CN (1) | CN1863798B (en) |
AT (1) | ATE448222T1 (en) |
AU (1) | AU2004278030C1 (en) |
CA (1) | CA2540214A1 (en) |
DE (1) | DE602004024093D1 (en) |
ES (1) | ES2334795T3 (en) |
HK (1) | HK1093973A1 (en) |
IL (1) | IL174446A (en) |
MX (1) | MXPA06003618A (en) |
PL (1) | PL1668002T3 (en) |
PT (1) | PT1668002E (en) |
WO (1) | WO2005032488A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7345049B2 (en) * | 2003-12-22 | 2008-03-18 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
EP1812429A4 (en) * | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
ZA200804241B (en) * | 2005-11-03 | 2009-09-30 | Portola Pharm Inc | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto |
US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
US7951813B2 (en) | 2007-04-05 | 2011-05-31 | Gilead Sciences, Inc. | Quinazolinone derivatives as ALDH-2 inhibitors |
TW200911755A (en) | 2007-04-19 | 2009-03-16 | Astellas Pharma Inc | Bicyclic heterocyclic compounds |
BRPI0810800A2 (en) * | 2007-05-02 | 2014-10-29 | Portola Pharm Inc | [4- (6-Fluoro-7-methylamino-2,4-dioxy-1,4-dihydro-2H-quinazolin-3-yl) -phenyl] -5-chlorine-thiophen-2-yl-s salts , FORMS AND METHODS RELATED TO THEM. |
CN101654441B (en) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | Anticoagulant compound, composition and application thereof |
KR20110116161A (en) * | 2009-01-19 | 2011-10-25 | 아보트 러보러터리즈 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AU2010204554B2 (en) | 2009-01-19 | 2013-05-30 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
EA026393B1 (en) * | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-substituted benzamides and their use in the treatment of pain |
KR101663436B1 (en) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-substituted benzamides and methods of use thereof |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | Substituted triazolopyridines and methods of use thereof |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
EP3450428A1 (en) | 2013-11-27 | 2019-03-06 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
MD3259253T2 (en) | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfonylureas and related compounds and use of same |
KR20180008761A (en) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | Substituted benzamides and methods for their use |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
JP2019513714A (en) | 2016-03-30 | 2019-05-30 | ジェネンテック, インコーポレイテッド | Substituted benzamides and methods of use thereof |
CA3039853A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP2020511511A (en) | 2017-03-24 | 2020-04-16 | ジェネンテック, インコーポレイテッド | 4-Piperidin-N- (pyrimidin-4-yl) chroman-7-sulfonamide derivatives as sodium channel inhibitors |
TWI789401B (en) | 2017-07-07 | 2023-01-11 | 愛爾蘭商英弗雷佐姆有限公司 | Novel compounds |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
UY37848A (en) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | SULFONILUREAS AND SULFONILTIOUREAS USEFUL AS INHIBITORS OF NLRP3 |
UY37847A (en) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | SULFONILUREAS AND SULFONILTIOUREAS USEFUL AS INHIBITORS OF NLRP3 |
TW202000651A (en) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Therapeutic compounds and methods of use thereof |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
CN111936494A (en) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | Substituted hydro-pyrido-azines as sodium channel inhibitors |
TW202039512A (en) | 2018-12-06 | 2020-11-01 | 日商第一三共股份有限公司 | Cycloalkane-1,3-diamine compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9702774D0 (en) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
CA2318199A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
ATE309999T1 (en) * | 2000-02-04 | 2005-12-15 | Portola Pharm Inc | PLATELE ADP RECEPTOR INHIBITORS |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
-
2004
- 2004-09-29 AU AU2004278030A patent/AU2004278030C1/en not_active Ceased
- 2004-09-29 KR KR1020067008644A patent/KR20060113700A/en not_active Application Discontinuation
- 2004-09-29 CA CA002540214A patent/CA2540214A1/en not_active Abandoned
- 2004-09-29 MX MXPA06003618A patent/MXPA06003618A/en active IP Right Grant
- 2004-09-29 PL PL04789522T patent/PL1668002T3/en unknown
- 2004-09-29 DE DE602004024093T patent/DE602004024093D1/en active Active
- 2004-09-29 EP EP04789522A patent/EP1668002B1/en active Active
- 2004-09-29 AT AT04789522T patent/ATE448222T1/en active
- 2004-09-29 US US10/956,004 patent/US7109332B2/en not_active Expired - Fee Related
- 2004-09-29 CN CN2004800287913A patent/CN1863798B/en not_active Expired - Fee Related
- 2004-09-29 PT PT04789522T patent/PT1668002E/en unknown
- 2004-09-29 WO PCT/US2004/032921 patent/WO2005032488A2/en active Application Filing
- 2004-09-29 ES ES04789522T patent/ES2334795T3/en active Active
- 2004-09-29 JP JP2006534290A patent/JP2007507551A/en active Pending
-
2006
- 2006-03-21 IL IL174446A patent/IL174446A/en not_active IP Right Cessation
- 2006-12-13 HK HK06113688.4A patent/HK1093973A1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
ES2334795T3 (en) | 2010-03-16 |
AU2004278030B2 (en) | 2010-07-01 |
AU2004278030C1 (en) | 2010-12-02 |
IL174446A (en) | 2012-02-29 |
CN1863798B (en) | 2011-08-31 |
MXPA06003618A (en) | 2006-08-11 |
PT1668002E (en) | 2009-11-25 |
WO2005032488A3 (en) | 2005-05-12 |
JP2007507551A (en) | 2007-03-29 |
WO2005032488A2 (en) | 2005-04-14 |
DE602004024093D1 (en) | 2009-12-24 |
US20050107357A1 (en) | 2005-05-19 |
EP1668002B1 (en) | 2009-11-11 |
US7109332B2 (en) | 2006-09-19 |
EP1668002A2 (en) | 2006-06-14 |
KR20060113700A (en) | 2006-11-02 |
AU2004278030A1 (en) | 2005-04-14 |
CA2540214A1 (en) | 2005-04-14 |
IL174446A0 (en) | 2006-08-01 |
ATE448222T1 (en) | 2009-11-15 |
CN1863798A (en) | 2006-11-15 |
PL1668002T3 (en) | 2010-02-26 |
HK1093973A1 (en) | 2007-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1093973A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
BG104248A (en) | Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides | |
MXPA04004457A (en) | Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators. | |
DE60330150D1 (en) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
DE50204803D1 (en) | 4-alkylsubstituierte thienyloxy-pyrididne als herbizide | |
IL157179A0 (en) | Fused heterocyclic compounds | |
HUP0402150A2 (en) | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity, process for the preparation, pharmaceutical compositions containing them and their use for production of pharmaceutical compositions | |
AU2886395A (en) | 2-{1',2',4'-triazol-3'-yloxymethylene}-anilides and their use as pest-control agents | |
NZ511311A (en) | Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives useful as agricultural, horticultural bactericides | |
WO2001017972A3 (en) | Novel herbicides | |
WO2003084937A3 (en) | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases | |
TW200609218A (en) | Bicyclic compounds | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
WO2004004730A3 (en) | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders | |
HRP20050082A2 (en) | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
MY146599A (en) | New azetidine compounds | |
DE60336735D1 (en) | NEW BIOLOGICAL MOLEKÜ LE | |
IL160874A0 (en) | 4-imidazolin-2-one derivatives | |
MXPA04003278A (en) | 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists. | |
PT1628968E (en) | 4-imidazolin-2-one compounds( | |
MXPA02003952A (en) | Imidazole derivatives as phosphodiesterase vii inhibitors. | |
ATE238300T1 (en) | (3,4-DIHYDRO-2H-BENZO(1,4)OXAZINYL-METHYL)-3-(1 - INDOL-3-YL)-ALKYLAMINES | |
MY139258A (en) | Carbamoyl-type benzofuran derivatives | |
GB0106419D0 (en) | Novel compounds | |
CA2009542A1 (en) | Cyclic guanidines as calcium antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060424 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20061121 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 409/12 20060101AFI20050602BHEP Ipc: A61P 7/02 20060101ALI20061115BHEP Ipc: A61K 31/517 20060101ALI20061115BHEP Ipc: C07D 409/14 20060101ALI20061115BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1093973 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20071227 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20091118 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: AMMANN PATENTANWAELTE AG BERN |
|
REF | Corresponds to: |
Ref document number: 602004024093 Country of ref document: DE Date of ref document: 20091224 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20100400172 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2334795 Country of ref document: ES Kind code of ref document: T3 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100211 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1093973 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100929 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20110923 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20110928 Year of fee payment: 8 Ref country code: TR Payment date: 20110906 Year of fee payment: 8 Ref country code: PL Payment date: 20110824 Year of fee payment: 8 Ref country code: GB Payment date: 20110920 Year of fee payment: 8 Ref country code: PT Payment date: 20110921 Year of fee payment: 8 Ref country code: GR Payment date: 20110923 Year of fee payment: 8 Ref country code: AT Payment date: 20110914 Year of fee payment: 8 Ref country code: DE Payment date: 20110923 Year of fee payment: 8 Ref country code: ES Payment date: 20110916 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20110926 Year of fee payment: 8 Ref country code: NL Payment date: 20110929 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20110914 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100929 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100512 |
|
BERE | Be: lapsed |
Owner name: PORTOLA PHARMACEUTICALS, INC. Effective date: 20120930 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20130401 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20130401 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 448222 Country of ref document: AT Kind code of ref document: T Effective date: 20120929 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20100400172 Country of ref document: GR Effective date: 20130404 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120929 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120929 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120929 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130403 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120929 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121001 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130401 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130404 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130401 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004024093 Country of ref document: DE Effective date: 20130403 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20131022 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120929 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 |